A topical quadruple-action combination used primarily for otological (ear) infections. It provides comprehensive management by combining a local anesthetic (Lidocaine) for pain relief, a broad-spectrum antifungal (Clotrimazole) for fungal eradication, a potent corticosteroid (Beclometasone) for anti-inflammatory and anti-pruritic effects, and a fluoroquinolone antibiotic (Ofloxacin) for antibacterial coverage against common ear pathogens. This formulation is particularly relevant in the Indian context for treating mixed or complicated otitis externa where bacterial, fungal, and inflammatory components coexist.
Adult: Instill 2-4 drops into the affected ear canal, 2-3 times daily. The patient should lie with the affected ear upward for 2-5 minutes after instillation.
Note: 1. Warm the bottle in hands before use to avoid vertigo from cold drops. 2. Clean and dry the outer ear gently. 3. Tilt head sideways. 4. Instill drops. 5. Maintain position for 2-5 minutes. 6. A loose cotton plug may be placed to prevent leakage. Do not insert deep into the canal. Avoid touching the dropper tip to any surface including the ear.
This combination exerts a multifaceted therapeutic action. Lidocaine blocks voltage-gated sodium channels in neuronal membranes, inhibiting depolarization and impulse conduction for local analgesia. Clotrimazole inhibits the synthesis of ergosterol, a critical component of fungal cell membranes, leading to increased membrane permeability and cell death. Beclometasone, a potent glucocorticoid, binds to intracellular receptors, modulating gene transcription to inhibit the production of pro-inflammatory cytokines, prostaglandins, and leukotrienes, thereby reducing inflammation, edema, and itching. Ofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair, leading to bactericidal activity.
Pregnancy: Category C (US FDA). Systemic corticosteroids and high-dose topical steroids are associated with risk. Lidocaine and Ofloxacin are Category B for topical use. Clotrimazole is Category B. Use only if the potential benefit justifies the potential risk to the fetus. Avoid large amounts or long-term use.
Driving: Usually safe. However, if dizziness or vertigo occurs as a side effect, patients should avoid driving or operating machinery.
| Other Topical Corticosteroids | Additive risk of skin atrophy, striae, and HPA axis suppression. | Major |
| Class I Antiarrhythmics (e.g., Mexiletine, Tocainide) | Additive cardiac effects (pro-arrhythmic potential) if lidocaine is absorbed systemically. | Moderate |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Erythromycin, Ritonavir) | May increase systemic levels of lidocaine and beclometasone if absorbed, increasing toxicity risk. | Moderate |
| Warfarin | Clotrimazole (systemic) can inhibit warfarin metabolism; theoretical risk with significant topical absorption. | Minor |
Same composition (Lidocaine (2% w/v) + Clotrimazole (1% w/v) + Beclometasone (0.025% w/v) + Ofloxacin (0.3% w/v)), different brands: